Objective To probe into the optimum therapy for hemiplegia induced by neurosurgical operation. Methods 50 cases were randomized into treatment group （25 cases） and control group （25 cases）. In control group, the r...Objective To probe into the optimum therapy for hemiplegia induced by neurosurgical operation. Methods 50 cases were randomized into treatment group （25 cases） and control group （25 cases）. In control group, the routine western drugs in internal medicine were applied; in treatment group, on the basis of the treatment in control group, acupuncture was supplemented 3 days after the operation. Acupoints were Neiguan （内关 PC 6）, Shuigou （水沟 GV26）, QSchi （ 曲池LI 11）, Hégü （合谷 LI 4）, Sanyinjiao （三阴交 SP 6）, Jiquan （极泉 HT 1）, Weizhong （委中BL 40）, etc. The scalp acupuncture was applied in combination. Such treatment was given for 30 days （once per day）. The functional evaluation was conducted based on neurological functional defect scale （NDS） before and after treatment. Results Acupuncture improved re markably NDS, the total effective rate was 76.0% in treatment group and was 42.4% in control group, indicating significant difference by statistical management （P〈0.05）. Conclusion The therapeutic effect in treatment group is superior to that in control group. The coordinative action is achieved in the combination of acupuncture with western medicine for hemiplegia after neurosurgical operation and the therapeutic effect is much improved.展开更多
Objective This study aimed to determine the ef icacy of chemotherapy and to identify potential chemo-therapy agents to treat advanced primary duodenal carcinoma （PDC）. Methods Seventy-three patients with advanced P...Objective This study aimed to determine the ef icacy of chemotherapy and to identify potential chemo-therapy agents to treat advanced primary duodenal carcinoma （PDC）. Methods Seventy-three patients with advanced PDC were included in the study. Response rate （RR）, disease control rate （DCR）, progression-free survival （PFS）, overal survival （OS） and prognosis were com-pared among patients using the Cox proportional hazards model. Results The overal RR and DCR of 52 patients were 21.15% and 69.23%, respectively. The median PFS and OS times were 4.51 and 11.47 months, respectively. Pal iative chemotherapy improved the OS of patients with advanced PDC compared with patients who did not receive chemotherapy （14.28 months vs. 5.20 months, HR = 0.205, 95% CI： 0.077 to 0.547, P = 0.0016）. Multivariate analysis indicated mucinous histology and liver metastasis as factors predictive of poor prognosis in patients with advanced PDC. Conclusion Pal iative chemotherapy may improve the OS of patients with advanced PDC. Mucinous histology and liver metastasis were the main prognostic factors in patients with advanced PDC.展开更多
Objective： Biological markers performable in routine practice and able to predict the clinical outcome of advanced non-small cell lung cancer （NSCLC） treated with gefitinib are urgently needed. Methods： We analyze...Objective： Biological markers performable in routine practice and able to predict the clinical outcome of advanced non-small cell lung cancer （NSCLC） treated with gefitinib are urgently needed. Methods： We analyzed EGFR / HER2 / HER3 primary tumour immunohistochemical expression in a prospective and consecutive series of 90 Chinese patients. Platinumpretreated patients received a 250 mg oral dose of gefitinib once daily until disease progression; EGFR / HER2 / HER3 tumour status was related with the clinical outcome in terms of response rate （RR）, time to disease progression （TTP）, and overall survival （OS）. Results： A high expression （scores 2-3） of EGFR, HER2 and HER3 was venfied in 16.7%, 43.3% and 21.1% of tumors, respectively. EGFR and HER3 status were not significantly related with response, while the HER2 overexpression result was significantly associated with a higher RR （35.9% vs. 15.7%, P = 0.027）. The RR in the 13 patients with both HER2 and HER3 expression was also significantly higher than in the other 77 patients （53.8% vs. 22.1%, P = 0.036）. EGFR / HER2 / HER3 status was not significantly correlated with TTP or OS. Conclusion： The HER2 immunohistochemical expression can play a role in the clinical management of Chinese patients with advanced NSCLC who are candidates for gefitinib therapy.展开更多
OBJECTIVE To analyze the long-term effects of treatment with an op-eration + postoperative irradiation (A group) and an operation+intraoperative radiotherapy+postoperative irradiation (B group) in non-small cell lung ...OBJECTIVE To analyze the long-term effects of treatment with an op-eration + postoperative irradiation (A group) and an operation+intraoperative radiotherapy+postoperative irradiation (B group) in non-small cell lung cancer patients. METHODS Through a prospective randomized clinical trial, a total of 154 patients with non-small cell lung carcinoma were divided into two groups of 77 cases. Among the 154 cases, there were 134 squamous carcinomas, 17 adenocarcinomas and 3 adeno-squamous carcinomas. TNM staging: there were 17 in StageⅠ, 76 in Stage Ⅱ and 61 in Stage Ⅲ. A dosage of 15～25 Gy IORT, energy 9～16 MeV electrons, was delivered to the tumors. The doses given were 40～60 Gy postoperation. RESULTS The local control rates in A and B groups were 49.4% and 62.3% respectively (P<0.05). The survivals at 3, 5 and 7 years for group A were 40.3%, 27.3%, and 5.2% and for group B 44.2%, 28.6% and 6.5% (P>0.05). There were 16 deaths from radiotherapy complications, with 2 cases in group A and 14 in group B. CONCLUSION IORT+postoperative irradiation can enhance the local control rate of non-small cell lung cancer patients and reduce the recurrent rates, but it can not improve long-term survival.展开更多
文摘Objective To probe into the optimum therapy for hemiplegia induced by neurosurgical operation. Methods 50 cases were randomized into treatment group （25 cases） and control group （25 cases）. In control group, the routine western drugs in internal medicine were applied; in treatment group, on the basis of the treatment in control group, acupuncture was supplemented 3 days after the operation. Acupoints were Neiguan （内关 PC 6）, Shuigou （水沟 GV26）, QSchi （ 曲池LI 11）, Hégü （合谷 LI 4）, Sanyinjiao （三阴交 SP 6）, Jiquan （极泉 HT 1）, Weizhong （委中BL 40）, etc. The scalp acupuncture was applied in combination. Such treatment was given for 30 days （once per day）. The functional evaluation was conducted based on neurological functional defect scale （NDS） before and after treatment. Results Acupuncture improved re markably NDS, the total effective rate was 76.0% in treatment group and was 42.4% in control group, indicating significant difference by statistical management （P〈0.05）. Conclusion The therapeutic effect in treatment group is superior to that in control group. The coordinative action is achieved in the combination of acupuncture with western medicine for hemiplegia after neurosurgical operation and the therapeutic effect is much improved.
文摘Objective This study aimed to determine the ef icacy of chemotherapy and to identify potential chemo-therapy agents to treat advanced primary duodenal carcinoma （PDC）. Methods Seventy-three patients with advanced PDC were included in the study. Response rate （RR）, disease control rate （DCR）, progression-free survival （PFS）, overal survival （OS） and prognosis were com-pared among patients using the Cox proportional hazards model. Results The overal RR and DCR of 52 patients were 21.15% and 69.23%, respectively. The median PFS and OS times were 4.51 and 11.47 months, respectively. Pal iative chemotherapy improved the OS of patients with advanced PDC compared with patients who did not receive chemotherapy （14.28 months vs. 5.20 months, HR = 0.205, 95% CI： 0.077 to 0.547, P = 0.0016）. Multivariate analysis indicated mucinous histology and liver metastasis as factors predictive of poor prognosis in patients with advanced PDC. Conclusion Pal iative chemotherapy may improve the OS of patients with advanced PDC. Mucinous histology and liver metastasis were the main prognostic factors in patients with advanced PDC.
文摘Objective： Biological markers performable in routine practice and able to predict the clinical outcome of advanced non-small cell lung cancer （NSCLC） treated with gefitinib are urgently needed. Methods： We analyzed EGFR / HER2 / HER3 primary tumour immunohistochemical expression in a prospective and consecutive series of 90 Chinese patients. Platinumpretreated patients received a 250 mg oral dose of gefitinib once daily until disease progression; EGFR / HER2 / HER3 tumour status was related with the clinical outcome in terms of response rate （RR）, time to disease progression （TTP）, and overall survival （OS）. Results： A high expression （scores 2-3） of EGFR, HER2 and HER3 was venfied in 16.7%, 43.3% and 21.1% of tumors, respectively. EGFR and HER3 status were not significantly related with response, while the HER2 overexpression result was significantly associated with a higher RR （35.9% vs. 15.7%, P = 0.027）. The RR in the 13 patients with both HER2 and HER3 expression was also significantly higher than in the other 77 patients （53.8% vs. 22.1%, P = 0.036）. EGFR / HER2 / HER3 status was not significantly correlated with TTP or OS. Conclusion： The HER2 immunohistochemical expression can play a role in the clinical management of Chinese patients with advanced NSCLC who are candidates for gefitinib therapy.
文摘OBJECTIVE To analyze the long-term effects of treatment with an op-eration + postoperative irradiation (A group) and an operation+intraoperative radiotherapy+postoperative irradiation (B group) in non-small cell lung cancer patients. METHODS Through a prospective randomized clinical trial, a total of 154 patients with non-small cell lung carcinoma were divided into two groups of 77 cases. Among the 154 cases, there were 134 squamous carcinomas, 17 adenocarcinomas and 3 adeno-squamous carcinomas. TNM staging: there were 17 in StageⅠ, 76 in Stage Ⅱ and 61 in Stage Ⅲ. A dosage of 15～25 Gy IORT, energy 9～16 MeV electrons, was delivered to the tumors. The doses given were 40～60 Gy postoperation. RESULTS The local control rates in A and B groups were 49.4% and 62.3% respectively (P<0.05). The survivals at 3, 5 and 7 years for group A were 40.3%, 27.3%, and 5.2% and for group B 44.2%, 28.6% and 6.5% (P>0.05). There were 16 deaths from radiotherapy complications, with 2 cases in group A and 14 in group B. CONCLUSION IORT+postoperative irradiation can enhance the local control rate of non-small cell lung cancer patients and reduce the recurrent rates, but it can not improve long-term survival.
